SciSparc Ltd

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2023

TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and dystonia known to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinson's disease.

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

“We hope the outcome of this trial will enable the Company to procced with commercialization process for SCI-210 in Israel" TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder ("ASD").

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

The treatment combines SciSparc's Palmitoylethanolamide (PEA) , the active pharmaceutical ingredient of its proprietary CannAmide ™ , and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

Apollomics Inc

Kaixin Auto Holdings

Reunion Neuroscience Inc

MultiMetaVerse Holdings Ltd

NanoViricides

Wearable Devices Ltd

Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.

The 7 Most Promising Penny Stocks to Buy in June

TEL AVIV, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it entered into a license and distribution agreement with SciSparc Nutraceuticals Inc. ("SciSparc Nutraceuticals"), a subsidiary in which the Company owns approximately a 51% equity interest, pursuant to which it granted SciSparc Nutraceuticals an exclusive license to sell and market CannAmide™ on the Amazon.com marketplace in Canada (“License Agreement”).

SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals

Topline results using the Company's SCI-110 met the trial's primary and secondary end points, demonstrating high safety profile and reduced agitation Topline results using the Company's SCI-110 met the trial's primary and secondary end points, demonstrating high safety profile and reduced agitation

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Amyris

Eos Energy Enterprises

If there's one thing we know now it's that catalysts play a significant role in trading penny stocks. This is where things like sympathy sentiment can play a much larger role.

Hot Penny Stocks To Watch After UCAR Stock Explodes

As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd.

SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

TEL AVIV, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its joint venture MitoCareX Bio , which focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins - promising transporting targets for innovating therapies.

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program

The C ompany previously announced positive interim results from the trial meeting its primary endpoints

SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a clinical trial

SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Upon the closing which occurred on March 22, 2023, the purchase price was adjusted from $2.5 million and increased to approximately $3 million.

SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million

Israeli Ministry of Health granted an approval to use SCI-110 in a clinical trial at the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel

SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully manufactured clinical batches of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb trial for Tourette Syndrome ("TS").

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

The cannabis oil will be use d as a part of the C ompany ' s proprietary SCI-210 treatment combination of CBD and CannAmide™

SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder

TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed a definitive agreement to sell a 49% interest in its wholly owned subsidiary, SciSparc Nutraceuticals Inc. (the “Subsidiary”), which owns WellutionTM , a top-selling Amazon.com Marketplace brand ("Wellution"), to a wholly-owned subsidiary of Jeffs' Brands Ltd. ("Jeffs' Brands")(Nasdaq: JFBR), a data-driven e-commerce company operating on Amazon, for $2.5 million in cash, subject to certain purchase price adjustments related to inventory and working capital expected to increase the purchase price by approximately $300,000, plus a mutual share exchange in the amount of $300,000 of ordinary shares from each of SciSparc and Jeffs' Brands. The number of shares in the share exchange will be calculated based on the average closing price of the relevant company's shares for 30 consecutive trading days ending on the third trading day immediately prior to closing the transaction. Following the closing of the transaction, which includes an equity conversion of financing amounts previously provided to the Subsidiary by SciSparc, SciSparc will hold approximately 51% of the Subsidiary.

SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million

Esports Technologies

Universal Security Instruments

How fundamental analysis helps investing in penny stocks The post The Role of Fundamental Analysis in Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Role of Fundamental Analysis in Penny Stock Investing

SciSparc (NASDAQ: SPRC ) stock is taking off on Friday as investors react to an update on its drug development joint venture. MitoCareX Bio is the joint venture behind today's rise.

Why Is SciSparc (SPRC) Stock Up 14% Today?

MitoCareX established its initial cloud-based computing infrastructure

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System

SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest

SciSparc Announces Corporate Restructuring plan

The Company is expected to evaluat e alternatives to  address potential short sales issue

SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares

The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment

News for SciSparc Ltd Stock (SPRC)